Research use only — not for human or veterinary use
Cagrilintide For Sale — 10 mg Vials and Cagri-Sema Research Blend
Cagrilintide is a long-acting synthetic analog of amylin, the 37-amino-acid hormone co-secreted with insulin from pancreatic beta cells. Native amylin is notoriously difficult to work with: it aggregates into insoluble fibrils within hours and has a half-life measured in minutes. Cagrilintide re-engineers the sequence for solubility and adds an acyl chain for albumin binding, producing a stable tool compound that laboratories can actually run in long-format assays. We supply it as a standalone 10 mg research vial and as a fixed-ratio blend with semaglutide for dual-pathway work. Research use only — not for human or veterinary use.
Compare Cagrilintide Research Options
The standalone vial isolates amylin-receptor signalling; the blend is intended for study designs that need amylin and GLP-1 pathways engaged from a single prepared solution.
| Option | Format | Suited to | Product page |
|---|---|---|---|
| Cagrilintide 10 mg | Lyophilized powder, single research vial | Isolated amylin and calcitonin receptor signalling studies | View Cagrilintide 10 mg → |
| Cagri-Sema 5 mg blend | Lyophilized co-formulated blend, single vial | Dual amylin + GLP-1 pathway models and combination screening | View Cagri-Sema 5 mg blend → |
What Is Cagrilintide?
Amylin is co-released with insulin and signals through a family of receptors formed when the calcitonin receptor associates with one of three receptor-activity-modifying proteins, producing the AMY1, AMY2 and AMY3 subtypes. Studying that system with native human amylin is impractical because the peptide self-associates into amyloid fibrils, the same aggregation chemistry implicated in islet amyloid deposits.
Cagrilintide addresses this with sequence substitutions borrowed in part from salmon calcitonin — a naturally non-fibrillating relative — combined with an acylation strategy similar to the one used in modern GLP-1 analogs. The result is a peptide that remains soluble in aqueous buffer across a realistic experimental window and binds albumin strongly enough to survive long incubations.
For a laboratory, the practical implication is that cagrilintide is the first amylin-family tool where an experiment can be designed around biology rather than around the peptide's tendency to fall out of solution. That is the reason it appears increasingly as the amylin arm in metabolic signalling panels.
Amylin Receptor Pharmacology
The AMY receptor subtypes are heterodimers: calcitonin receptor plus RAMP1, RAMP2 or RAMP3. Because the RAMP partner reshapes the ligand-binding pocket, selectivity profiling requires expressing each subtype separately, and a compound's apparent potency can shift by an order of magnitude between them. Any serious cagrilintide characterisation therefore runs a subtype panel rather than a single cell line.
Downstream signalling is again predominantly cAMP-mediated, but amylin-receptor research has a strong secondary focus on area postrema and hindbrain receptor populations, where the physiological literature places much of amylin's activity. In vitro work in those models looks at receptor expression and downstream activation markers rather than at systemic outcomes.
Cross-reactivity with the parent calcitonin receptor matters for interpretation. A response observed in a RAMP-null background is calcitonin-receptor-mediated, not amylin-receptor-mediated, and study designs that omit that control routinely over-attribute effects to the AMY subtypes.
Cagrilintide Alone vs. the Cagri-Sema Blend
The standalone 10 mg vial is the right tool when the experimental question concerns amylin-receptor pharmacology itself: subtype selectivity, aggregation behaviour, binding kinetics, or comparison against calcitonin-family reference peptides. Because nothing else is in the vial, the concentration is unambiguous and dilution series are straightforward.
The Cagri-Sema blend is a co-formulated, fixed-ratio preparation of cagrilintide with semaglutide. It exists for study designs investigating combined amylin and GLP-1 receptor engagement, where the point is the interaction between the two pathways and where preparing a consistent two-peptide solution by hand introduces avoidable ratio error.
The trade-off is control: a blend cannot be titrated independently. If a protocol needs to vary the amylin and GLP-1 arms separately, buy the standalone cagrilintide vial alongside a semaglutide vial and prepare the combination in-house with documented ratios.
Research Applications
Cagrilintide is used in receptor-binding and displacement work across AMY1-3 and calcitonin receptor lines, cAMP accumulation assays, aggregation and thioflavin-T fibrillation studies where it functions as the non-fibrillating comparator to native amylin, and combination screens with incretin analogs.
Analytical laboratories also use it in stability-indicating method development. Its aggregation resistance relative to native amylin makes it a useful benchmark when validating that a chromatographic method can actually resolve aggregated from monomeric species.
In comparative metabolic panels, cagrilintide occupies a distinct position: it is not an incretin analog at all, so it provides an orthogonal signalling arm against tirzepatide, semaglutide and retatrutide rather than a variation on the same theme.
- AMY1/AMY2/AMY3 subtype selectivity panels
- Aggregation and fibrillation comparison against native amylin
- Combination screening with GLP-1 receptor agonists
- Stability-indicating analytical method validation
Handling Notes Specific to Amylin-Family Peptides
Shear is the enemy. Amylin-family peptides nucleate fibrils at air-liquid interfaces and under mechanical agitation, so vortexing, shaking, and repeated aggressive pipetting all measurably increase aggregate content. Reconstitute by wall-directed addition and gentle swirling, and pipette slowly with wide-bore tips where available.
Buffer choice matters more than for incretin analogs. pH near the isoelectric region reduces solubility and accelerates association; most laboratories work slightly away from it and document the buffer system in full, because aggregation results are not comparable across different diluents.
Inspect solutions before use. A faint haze or a slight increase in viscosity indicates early aggregation, and material in that state should not enter a quantitative assay. Store reconstituted solution at 2–8 °C, keep the working window short, and aliquot at the point of reconstitution rather than cycling one vial repeatedly.
Material Specifications
- Compound
- Cagrilintide (long-acting amylin analog)
- Class
- AMY receptor / calcitonin receptor agonist
- Related target
- Calcitonin receptor with RAMP1-3 co-receptors
- Appearance
- White to off-white lyophilized powder
- Purity
- ≥ 99% by reverse-phase HPLC
- Storage
- Sealed vials frozen or 2–8 °C; solution 2–8 °C
- Aggregation note
- Avoid agitation — amylin-family peptides fibrillate under shear
- Use
- In vitro laboratory research only
Purity, Testing & Certificates of Analysis
Cagrilintide and the Cagri-Sema blend are released against reverse-phase HPLC purity criteria with mass-spectrometry identity confirmation. For the blend, the release review additionally confirms that both components are present and resolvable, since a co-formulated product whose ratio cannot be verified chromatographically is unusable as a quantitative research article.
Because amylin-family peptides can aggregate during handling and shipping, appearance and reconstitution behaviour are recorded at release alongside the numerical purity figure. A certificate that reports purity without recording appearance tells a laboratory very little about aggregation state.
Each shipment references a dated, lot-specific Certificate of Analysis that remains retrievable after purchase, and the full certificate library is published rather than sampled.
Research FAQ
What is cagrilintide?
Cagrilintide is a long-acting synthetic analog of amylin, engineered for solubility and albumin binding so that it resists the fibril formation that makes native human amylin impractical to work with. In research it is used as the reference amylin-receptor agonist for in vitro signalling and binding studies.
What is the difference between cagrilintide and the Cagri-Sema blend?
The 10 mg vial contains cagrilintide alone, which keeps concentrations unambiguous for amylin-receptor pharmacology. The Cagri-Sema 5 mg product is a fixed-ratio co-formulation with semaglutide for study designs that need amylin and GLP-1 pathways engaged together; its ratio cannot be varied independently.
Which receptors does cagrilintide act on?
It engages the amylin receptor subtypes AMY1, AMY2 and AMY3, which form when the calcitonin receptor associates with RAMP1, RAMP2 or RAMP3, and it retains activity at the parent calcitonin receptor. Selectivity profiling requires expressing the subtypes separately, since the RAMP partner reshapes the binding pocket.
Why does cagrilintide need gentler handling than a GLP-1 analog?
Amylin-family peptides nucleate fibrils at air-liquid interfaces and under shear. Vortexing, shaking, and aggressive pipetting raise aggregate content measurably, so reconstitution should be wall-directed and swirled gently, and solutions showing haze or increased viscosity should be excluded from quantitative assays.
What purity is your cagrilintide?
Cagrilintide is released at ≥99% chromatographic purity by reverse-phase HPLC with mass-spectrometry identity confirmation. For the blend, release additionally confirms both components are present and chromatographically resolvable, and appearance is recorded because it reflects aggregation state.
Can cagrilintide be compared against GLP-1 agonists?
Yes, and it is often included precisely because it is not an incretin analog. Cagrilintide provides an orthogonal amylin-receptor arm alongside semaglutide, tirzepatide, or retatrutide, which makes combination and pathway-interaction questions tractable in a single comparative panel.
How is cagrilintide stored?
Keep sealed vials frozen for long-term holding or refrigerated at 2–8 °C for shorter periods, protected from light and moisture. After reconstitution, store at 2–8 °C, keep the working window short, and aliquot at the point of reconstitution rather than repeatedly cycling a single vial.
Is cagrilintide supplied for human use?
No. Cagrilintide and the Cagri-Sema blend are supplied exclusively as research chemicals for qualified in vitro laboratory work. They are not medicines, supplements, or products for human or veterinary consumption, and we do not provide dosing or protocol guidance of any kind.
Research Resources
All products listed are supplied strictly for in vitro laboratory research by qualified professionals. Not for human or veterinary use. We do not provide dosing guidance or therapeutic recommendations, and nothing on this page describes a diagnosis, treatment, cure, or prevention of any condition.